Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis

Arthritis and Rheumatism

Volumn 56, Issue 7, 2007, Pages 2143-2149

  Patel, Sanjeev ^a,b   Farragher, Tracey ^c   Berry, Jacqueline ^d   Bunn, Diane ^e   Silman, Alan ^c   Symmons, Deborah ^c  

^a EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^e NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; BODY MASS; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; METABOLITE; ONSET AGE; POLYARTHRITIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VITAMIN BLOOD LEVEL;

ANTIRHEUMATIC AGENTS; ARTHRITIS; BIOLOGICAL MARKERS; CALCIFEDIOL; CALCITRIOL; FEMALE; HUMANS; INFLAMMATION; JOINTS; MALE; PATIENT SELECTION;

EID: 34547421856     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22722     Document Type: Article

References (23)

1. Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-Grand) 2003;49:277-300.
2. Griffin MD, Xing N, Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Ann Rev Nutr 2003;23:117-45.
3. 3, and the immune system. Am J Clin Nutr 2004;80:1717-20S.
4. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005;26:662-87.
5. Lemire JM. Immunomodulatory role of 1,25 dihydroxyvitamin D. J Cell Biochem 1992;49:26-31.
6. Cantorna MT, Hayes CE, DeLuca HF. 1,25-dihydroxyvitamin D reversibly blocks the progression of relapsing encephalomyelitis. Proc Natl Acad Sci U S A 1996;93:7861-4.
7. Cantorna MT, Hayes CE, DeLuca HF. 1,25-dihydroxyvitamin D inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998;128:68-72.
8. Tetlow LC, Smith SJ, Mawer EB, Woolley DE. Vitamin D receptors in the rheumatoid lesion: expression by chondrocytes, macrophages and synoviocytes. Ann Rheum Dis 1999;58:118-21.
9. Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Vitamin D is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2004:50;72-7.
10. Garcia-Lozano JR, Gonzalez-Escribano MF, Valenzuela A, Garcia A, Nunez-Roldan A. Association of vitamin D receptor genotypes with early onset rheumatoid arthritis. Eur J Immunogenet 2001;28:89-93.
11. Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994;33:735-9.
12. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-9.
13. Bukhari M, Harrison B, Lunt M, Scott DG, Symmons DP, Silman AJ. Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis Rheum 2001;44:1248-53.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
15. Wiles N, Symmons DP, Harrison B, Barrett E, Barrett JH, Scott DG, et al. Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum 1999;42:1339-46.
16. Mawer EB, Hann J, Berry JL, Davies M. Vitamin D metabolism in patients intoxicated with ergocalciferol. Clin Sci (Lond) 1985;68: 135-41.
17. Mawer EB, Berry JL, Cundall JP, Still PE, White A. A sensitive radioimmunoassay that is equipotent for ergocalcitriol and calcitriol (1,25-dihydroxyvitamin D2 and D3). Clin Chim Acta 1990;190: 199-210.
18. Berry JL, Martin J, Mawer EB. 25-Hydroxyvitamin D assay kits: speed at the cost of accuracy? In: Norman AW, Bouillion R, Thomasset M, editors. Vitamin D endocrine system: structural, biological, genetic and clinical aspects. Riverside (CA): University of California; 2000. p. 797-800.
19. Mawer EB, Hayes ME, Still PE, Davies M, Lumb GA, Palit J, et al. Evidence for nonrenal synthesis of 1,25-dihydroxyvitamin D in patients with inflammatory arthritis. J Bone Miner Res 1991;6: 733-9.
20. Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A, Mitrovic D, et al. Disease modifying and immunomodulatory effects of high dose 1α (OH)D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999;17:453-6.
21. Kroger H, Penttila IM, Alhava EM. Low serum vitamin D metabolites in women with rheumatoid arthritis. Scand J Rheumatol 1993;22:172-7.
22. Oelzner P, Miller A, Deschner F, Huller M, Abendroth K, Hein G, et al. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998;62:193-8.
23. Lucas JA, Bolland MJ, Grey AB, Ames RW, Mason BW, Horne AM, et al. Determinants of vitamin D status in older women living in a subtropical climate. Osteoporosis Int 2005;16:1641-8.